{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:01:33Z","timestamp":1782903693722,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","award":["602570"],"award-info":[{"award-number":["602570"]}],"id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3409-1","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T14:03:13Z","timestamp":1560780193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy"],"prefix":"10.1186","volume":"20","author":[{"name":"on behalf of the iHIVARNA consortium","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9674-2647","authenticated-orcid":false,"given":"Wesley","family":"de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joeri","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefien","family":"Buyze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Florence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"van Gorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Vanham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Thielemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Plana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lipe","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Gruters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"3409_CR1","unstructured":"WHO. HIV\/AIDS data and statistics: World Health Organization; 2017. Available from: \nhttp:\/\/www.who.int\/hiv\/data\/en\/\n\n. Accessed 11 May 2017."},{"issue":"8","key":"3409_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/00002030-199607000-00009","volume":"10","author":"AN Phillips","year":"1996","unstructured":"Phillips AN, Eron JJ, Bartlett JA, Rubin M, Johnson J, Price S, et al. HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. AIDS. 1996;10(8):859\u201365.","journal-title":"AIDS"},{"issue":"6","key":"3409_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nm880","volume":"9","author":"JD Siliciano","year":"2003","unstructured":"Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9(6):727\u20138.","journal-title":"Nat Med"},{"key":"3409_CR4","unstructured":"WHO. Prevent HIV, test and treat all\u2014WHO support for country impact. Progress report 2016: WHO; 2016. \nhttps:\/\/www.who.int\/hiv\/pub\/progressreports\/2016-progress-report\/en\/\n\n. Accessed 11 May 2017."},{"issue":"6","key":"3409_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/14760584.2017.1322513","volume":"16","author":"L Leal","year":"2017","unstructured":"Leal L, Lucero C, Gatell JM, Gallart T, Plana M, Garcia F. New challenges in therapeutic vaccines against HIV infection. Expert Rev Vaccines. 2017;16(6):587\u2013600.","journal-title":"Expert Rev Vaccines"},{"issue":"6193","key":"3409_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1126\/science.1255512","volume":"345","author":"DH Barouch","year":"2014","unstructured":"Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345(6193):169\u201374.","journal-title":"Science"},{"issue":"1","key":"3409_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/imr.12083","volume":"254","author":"G Carcelain","year":"2013","unstructured":"Carcelain G, Autran B. Immune interventions in HIV infection. Immunol Rev. 2013;254(1):355\u201371.","journal-title":"Immunol Rev"},{"issue":"166","key":"3409_CR8","doi-asserted-by":"publisher","first-page":"166ra2","DOI":"10.1126\/scitranslmed.3004682","volume":"5","author":"F Garcia","year":"2013","unstructured":"Garcia F, Climent N, Guardo AC, Gil C, Leon A, Autran B, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med. 2013;5(166):166ra2.","journal-title":"Sci Transl Med"},{"key":"3409_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12967-015-0392-5","volume":"13","author":"B Mothe","year":"2015","unstructured":"Mothe B, Hu X, Llano A, Rosati M, Olvera A, Kulkarni V, et al. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med. 2015;13:60.","journal-title":"J Transl Med"},{"issue":"6","key":"3409_CR10","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/mt.2008.77","volume":"16","author":"A Bonehill","year":"2008","unstructured":"Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 2008;16(6):1170\u201380.","journal-title":"Mol Ther"},{"key":"3409_CR11","unstructured":"AETC. HIV Classification: CDC and WHO Staging Systems: AIDS Education & Training Center Program; 2014. [Available from: \nhttps:\/\/aidsetc.org\/guide\/hiv-classification-cdc-and-who-staging-systems\n\n. Accessed 11 May 2017."},{"key":"3409_CR12","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"5","key":"3409_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/QAD.0000000000000987","volume":"30","author":"R Calin","year":"2016","unstructured":"Calin R, Hamimi C, Lambert-Niclot S, Carcelain G, Bellet J, Assoumou L, et al. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. AIDS. 2016;30(5):761\u20139.","journal-title":"AIDS"},{"issue":"5919","key":"3409_CR14","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1126\/science.1165706","volume":"323","author":"DD Richman","year":"2009","unstructured":"Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323(5919):1304\u20137.","journal-title":"Science"},{"issue":"1","key":"3409_CR15","doi-asserted-by":"publisher","first-page":"e29717","DOI":"10.1371\/journal.pone.0029717","volume":"7","author":"B Mothe","year":"2012","unstructured":"Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, Miranda C, et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One. 2012;7(1):e29717.","journal-title":"PLoS One"},{"issue":"2","key":"3409_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","volume":"4","author":"S Van Lint","year":"2016","unstructured":"Van Lint S, Renmans D, Broos K, Goethals L, Maenhout S, Benteyn D, et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res. 2016;4(2):146\u201356.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"3409_CR17","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00262-014-1558-3","volume":"63","author":"S Van Lint","year":"2014","unstructured":"Van Lint S, Wilgenhof S, Heirman C, Corthals J, Breckpot K, Bonehill A, et al. Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunol Immunother. 2014;63(9):959\u201367.","journal-title":"Cancer Immunol Immunother"},{"issue":"7632","key":"3409_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nature20583","volume":"540","author":"EN Borducchi","year":"2016","unstructured":"Borducchi EN, Cabral C, Stephenson KE, Liu J, Abbink P, Ng'ang'a D, et al. Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature. 2016;540(7632):284\u20137.","journal-title":"Nature"},{"issue":"3","key":"3409_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clim.2011.10.010","volume":"142","author":"SD Allard","year":"2012","unstructured":"Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML, et al. A phase I\/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol. 2012;142(3):252\u201368.","journal-title":"Clin Immunol"},{"issue":"11","key":"3409_CR20","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","volume":"15","author":"KJ Kauffman","year":"2015","unstructured":"Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW, DeRosa F, Mir FF, et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 2015;15(11):7300\u20136.","journal-title":"Nano Lett"},{"issue":"3","key":"3409_CR21","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","volume":"17","author":"MA Oberli","year":"2017","unstructured":"Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017;17(3):1326\u201335.","journal-title":"Nano Lett"},{"issue":"3","key":"3409_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jconrel.2010.10.020","volume":"150","author":"G Tavernier","year":"2011","unstructured":"Tavernier G, Andries O, Demeester J, Sanders NN, De Smedt SC, Rejman J. mRNA as gene therapeutic: how to control protein expression. J Control Release. 2011;150(3):238\u201347.","journal-title":"J Control Release"},{"issue":"2","key":"3409_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4161\/hv.22661","volume":"9","author":"S Van Lint","year":"2013","unstructured":"Van Lint S, Heirman C, Thielemans K, Breckpot K. mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother. 2013;9(2):265\u201374.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"3409_CR24","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/infdis\/jiu534","volume":"211","author":"M Ruiz-Riol","year":"2015","unstructured":"Ruiz-Riol M, Llano A, Ibarrondo J, Zamarreno J, Yusim K, Bach V, et al. Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. J Infect Dis. 2015;211(6):936\u201346.","journal-title":"J Infect Dis"},{"key":"3409_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jim.2017.03.014","volume":"445","author":"J Dock","year":"2017","unstructured":"Dock J, Hultin L, Hultin P, Elliot J, Yang OO, Anton PA, et al. Human immune compartment comparisons: optimization of proliferative assays for blood and gut T lymphocytes. J Immunol Methods. 2017;445:77\u201387.","journal-title":"J Immunol Methods"},{"issue":"9","key":"3409_CR26","doi-asserted-by":"publisher","first-page":"e74855","DOI":"10.1371\/journal.pone.0074855","volume":"8","author":"O Lambotte","year":"2013","unstructured":"Lambotte O, Pollara J, Boufassa F, Moog C, Venet A, Haynes BF, et al. High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS One. 2013;8(9):e74855.","journal-title":"PLoS One"},{"issue":"4","key":"3409_CR27","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/QAD.0b013e32834f33e8","volume":"26","author":"E Van Gulck","year":"2012","unstructured":"Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS. 2012;26(4):F1\u201312.","journal-title":"AIDS"},{"issue":"25","key":"3409_CR28","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1016\/j.vaccine.2015.04.047","volume":"33","author":"AL de Goede","year":"2015","unstructured":"de Goede AL, Andeweg AC, van den Ham HJ, Bijl MA, Zaaraoui-Boutahar F, van IJcken WF, et al. DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift. Vaccine. 2015;33(25):2922\u20139.","journal-title":"Vaccine"},{"issue":"17","key":"3409_CR29","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1097\/01.aids.0000433813.67662.92","volume":"27","author":"AL de Goede","year":"2013","unstructured":"de Goede AL, van Deutekom HW, Vrancken B, Schutten M, Allard SD, van Baalen CA, et al. HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption. AIDS. 2013;27(17):2679\u201389.","journal-title":"AIDS"}],"updated-by":[{"DOI":"10.1186\/s13063-019-3940-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3409-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3409-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3409-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T23:23:04Z","timestamp":1592263384000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3409-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3409"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3409-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13063-019-3940-0","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"10 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1], we have been notified that end note would need to be adjusted.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not provided.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"Ethics approval has been obtained from:The Netherlands: CCMO (leading Ethical Committee) NL57593.000.16 dd. 6 February 2017MEC of Erasmus MC: dossier ABR: NL57593.000.16 dd. 15 March 2017Belgium: Leading Ethical Committee UZ Brussels 2016\/316 dd. 22 February 2017Spain: CEIm, Hospital Clinic Barcelona, 25\/2016 dd. 23 December 2016Participants provide written informed consent before screening. Participants have the opportunity to review written consent with the investigator, ask questions and clarification. An optional two week consideration period is offered.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CB and BM are co-inventors of the HTI immunogen sequence. CB is CSO of, and receives compensation from, AELIX Therapeutics, a Barcelona biotech company developing HTI in the context of different vaccine vectors. BM is a consultant for AELIX Therapeutics. KT is the founder and SCO of eTheRNA and receives compensation from eTheRNA, a Brussels immunotherapy spin-off company of Vrije Universiteit Brussel. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"361"}}